A proof-of-concept study: Mirabegron, a new therapy for overactive bladder

Neurourology and Urodynamics

Volumn 32, Issue 8, 2013, Pages 1116-1122

  Chapple, Christopher R ^a   Amarenco, Gerard ^b   Lõpez Aramburu, Miguel A ^c   Everaert, Karel ^d   Liehne, Josef ^e   Lucas, Malcolm ^f   Vik, Viktor ^g   Ridder, Arwin ^h   Snijder, Robert ^h   Yamaguchi, Osamu ⁱ  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b HÔPITAL TENON   (France)

^c Unidad de Enfermeria Urologica Hospital Santiago Apostol Miranda de Ebro Burgos Espana   (Spain)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e Ustecke Urocentrum   (Czech Republic)

^f MORRISTON HOSPITAL   (United Kingdom)

^g Tomayerova Nemocnice   (Czech Republic)

^h Astellas Pharma Global Development   (Netherlands)

ⁱ NIHON UNIVERSITY   (Japan)

Author keywords

3 adrenoceptor agonist; overactive bladder; phase 2 study

Indexed keywords

MIRABEGRON; PLACEBO; TOLTERODINE;

ADULT; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EYE DISEASE; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NOCTURIA; OVERACTIVE BLADDER; PHASE 2 CLINICAL TRIAL; POSTVOID RESIDUAL URINE VOLUME; PULSE RATE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; VASCULAR DISEASE; VERTIGO; VOMITING; XEROSTOMIA;

OVERACTIVE BLADDER; PHASE 2 STUDY; Β3-ADRENOCEPTOR AGONIST;

ACETANILIDES; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NOCTURIA; QUALITY OF LIFE; THIAZOLES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINATION; UROLOGICAL AGENTS;

EID: 84886394357     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22373     Document Type: Article

References (17)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
2. Sexton CC, Coyne KS, Kopp ZS, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS BJU Int 2009; 103: 12-23.
3. Michel MC, Chapple CR,. Basic mechanisms of urgency: Preclinical and clinical evidence. Eur Urol 2009; 56: 298-307.
4. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006; 148: 565-78.
5. Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010; 105: 1276-82.
6. Igawa Y, Yamazaki Y, Takeda H, et al. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 1999; 126: 819-25.
7. Takeda M, Obara K, Mizusawa T, et al. Evidence for β3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: Analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 1999; 288: 1367-73.
8. Fujimura T, Tamura K, Tsutsumi T, et al. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol 1999; 161: 680-5.
9. Nomiya M, Yamaguchi O,. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003; 170: 649-53.
10. Kumar V, Templeman L, Chapple CR, et al. Recent developments in the management of detrusor overactivity. Curr Opin Urol 2003; 13: 285-91.
11. Basra R, Kelleher C,. Disease burden of overactive bladder: Quality-of-life data assessed using ICI-recommended instruments. Pharmacoeconomics 2007; 25: 129-42.
12. Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): A single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 1079-86.
13. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10.
14. 3-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs 2010; 13: 713-22.
15. Yamaguchi O, Chapple CR,. Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn 2007; 26: 752-6.
16. Van Kerrebroeck P, Kreder K, Jonas V, et al. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001; 57: 414-21.
17. Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: A network meta-analytic approach. PLoS ONE 2011; 6: e16718.